EGFR and non-small cell lung carcinoma: However, some reports, such as a 2022 prospective study [23], showed no significant prognostic impact in multivariate analysis for first‐line TKI‐treated advanced NSCLC (p = 0.321), though EGFR amplification was linked to a higher risk of brain metastasis (p = 0.047).